C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma
Showing 1 - 25 of >10,000
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)
Not yet recruiting
- High-grade B-cell Lymphoma
- +8 more
- Sepantronium Bromide
-
Busan, Korea, Republic of
- +5 more
Feb 27, 2022
DLBCL, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6
Recruiting
- Diffuse Large B-Cell Lymphoma
- +2 more
- Prednisone
- +6 more
-
Tampa, Florida
- +1 more
Jan 12, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +10 more
- Bortezomib
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- +8 more
- Biospecimen Collection
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 8, 2023
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by
Active, not recruiting
- Non Hodgkin Lymphoma
- +4 more
- DA-EPOCH-R followed by Nivolumab
-
Antwerpen, Belgium
- +23 more
Mar 23, 2022
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma Trial in Worldwide (RO6870810, Venetoclax, Rituximab)
Completed
- Diffuse Large B-cell Lymphoma
- High-Grade B-cell Lymphoma
- RO6870810
- +2 more
-
Duarte, California
- +8 more
Jan 21, 2022
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between
Not yet recruiting
- Recurrent ALK Positive Large B-Cell Lymphoma
- +28 more
- Biospecimen Collection
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 17, 2022
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6
Withdrawn
- Recurrent Diffuse Large B-Cell Lymphoma
- +9 more
- Autologous Hematopoietic Stem Cell Transplantation
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6
Not yet recruiting
- Grade 3b Follicular Lymphoma
- +5 more
- Biospecimen Collection
- +9 more
- (no location specified)
Jun 6, 2023
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,
Suspended
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
- +20 more
- Cyclophosphamide
- +6 more
-
Tucson, Arizona
- +110 more
Jan 31, 2023
Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,
Recruiting
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Scottsdale, Arizona
- +2 more
Jun 1, 2022
High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,
Recruiting
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- +4 more
- Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
- R-CHOP; R-DA-EPOCH; R-HD MTX
-
Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital
Dec 7, 2021
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified,
Recruiting
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- +4 more
- Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
-
Jinan, Shandong, ChinaShandong Provincial Hospital
Nov 18, 2021
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 18, 2022
DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle
Terminated
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +5 more
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 1, 2022
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent
Recruiting
- Clonal Cytopenia of Undetermined Significance
- +6 more
- Ascorbic Acid
- +12 more
-
Scottsdale, Arizona
- +4 more
May 26, 2022
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,
Suspended
- Burkitt Lymphoma
- +4 more
- Rituximab
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023